The discovery analysis displayed a remarkable 95% sensitivity and 98% specificity in detecting pancreatic cancer from blood samples.

Mainz Biomed has secured an exclusive license for the mRNA biomarker portfolio and will continue developing a machine learning AI algorithm based on Liquid Biosciences’ EMERGE platform.

BERKELEY, Calif. and MAINZ, Germany, March 13, 2025 — Mainz Biomed N.V., a molecular genetics diagnostics company focused on early cancer detection, has announced an agreement with Liquid Biosciences to license a collection of innovative mRNA biomarkers. This agreement enables Mainz Biomed to develop a non-invasive blood test for pancreatic cancer detection. The companies intend to collaborate on developing this test for potential FDA approval.

According to the agreement, Mainz Biomed gains exclusive rights to develop a test utilizing Liquid Biosciences’ biomarkers through an exclusive license. They also have the option to acquire global rights to these gene expression biomarkers, which have proven highly effective in pancreatic cancer detection. The financial details of the agreement include a license fee and royalties on future revenues if the option is exercised.

The discovery process involved several independent studies of pancreatic cancer. Liquid Biosciences employed their EMERGE platform to identify a selection of relevant mRNA biomarkers from blood samples of 285 subjects, including 35 pancreatic cancer patients. The biomarkers were further validated in two additional independent groups, which confirmed the strong clinical contribution of each biomarker that was indicated during the initial discovery phase. The analysis revealed that the biomarkers, combined with Liquid Biosciences’ algorithm, achieved 95% sensitivity and 98% specificity in detecting pancreatic cancer. If these statistical results are repeatable upon integration into a new product, the company’s test has the potential to become the most reliable and accurate screening tool for pancreatic cancer available.

“Obtaining exclusive licensing rights to this set of novel biomarkers marks a significant achievement and an expansion of our previously announced PancAlert program. This presents us with an exceptional chance to enhance early detection and diagnosis of one of the most difficult-to-treat cancers. We believe this progress represents a fundamental change in how we can detect pancreatic cancer,” stated Guido Baechler, CEO of Mainz Biomed.

The companies are planning a joint effort to develop this pancreatic cancer screening test, including enhancing commercial assays, improving algorithms, and preparing for possible FDA application and approval.

Please follow us to stay up to date:

About Mainz Biomed NV
Mainz Biomed creates molecular genetic diagnostic solutions ready for the market for life-threatening diseases. ColoAlert®, the company’s main product, is an accurate, non-invasive, user-friendly diagnostic test for early detection of colorectal cancer that is sold throughout Europe. The company is currently conducting a study to finalize the next-generation CRC screening test in preparation for the pivotal FDA clinical study needed for US regulatory approval. Mainz Biomed’s product line also features PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers. To learn more, visit or follow us on , and .

For media inquiries

MC Services AG
Anne Hennecke / Simone Neeten
+49 211 529252 17

For investor inquiries, please contact

Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995’s “safe harbor” provisions. These statements can be identified by terms like “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” as well as similar expressions that predict or indicate future events or trends, or that are not statements of historical fact. These forward-looking statements represent the current analysis of existing information and are subject to various risks and uncertainties. Consequently, caution should be exercised when relying on them. Due to known and unknown risks, actual results may significantly differ from the Company’s expectations or projections. Factors that could cause actual results to differ materially include: (i) failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; and (iii) other risks and uncertainties described herein, as well as those discussed in the Company’s reports and public filings with the Securities and Exchange Commission (the “SEC”). Further information regarding these and other factors that may affect the Company’s expectations and projections is available in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings can be accessed on the SEC’s website at www.sec.gov. Any forward-looking statement made in this press release is based solely on information currently available to Mainz Biomed and is valid only as of the date it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

“`